Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sutro Biopharma (STRO) EBT (2017 - 2025)

Sutro Biopharma (STRO) has disclosed EBT for 9 consecutive years, with $144.3 million as the latest value for Q4 2025.

  • Quarterly EBT fell 6.89% to $144.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$88.6 million for FY2023, 24.08% up from the prior year.
  • EBT hit $144.3 million in Q4 2025 for Sutro Biopharma, up from -$56.9 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $155.0 million in Q4 2024 to a low of -$65.3 million in Q1 2025.
  • Historically, EBT has averaged -$14.5 million across 5 years, with a median of -$36.4 million in 2021.
  • Biggest five-year swings in EBT: plummeted 282.18% in 2022 and later skyrocketed 235.49% in 2023.
  • Year by year, EBT stood at -$38.1 million in 2021, then rose by 9.26% to -$34.6 million in 2022, then surged by 235.49% to $46.9 million in 2023, then skyrocketed by 230.71% to $155.0 million in 2024, then fell by 6.89% to $144.3 million in 2025.
  • Business Quant data shows EBT for STRO at $144.3 million in Q4 2025, -$56.9 million in Q3 2025, and -$11.5 million in Q2 2025.